Radioimmunoassays for phenothiazine drugs and their major metabolites in plasma.
Radioimmunoassay procedures have been developed for some phenothiazine drugs and their major metabolites which are capable of quantitating 0.3 ng/ml or less in a 200 microliter plasma sample with a coefficient of variation less than 3%. They were developed with a view to their use in pilot investigations of plasma level versus clinical response correlations. The development of the procedures for trifluoperazine are described in this workshop. Antisera to trifluoperazine have been raised in New Zealand white rabbits to several different types of immunogens, where there was variation in the length and nature of the N-10 side chain attached to the phenothiazine nucleus, as well as in the number of hapten residues coupled to bovine serum albumin. An improved radioimmunoassay for trifluoperazine has been developed which showed cross-reactivities to the N-desmethyl and 7-hydroxy metabolites of trifluoperazine of the order of 12 and 11%, respectively, in comparison to the 26 and 24% cross-reactivity, respectively, for the same metabolites by a previously reported procedure.
D014150:Antipsychotic Agents / Q000097:blood*; D001711:Biotransformation; D008401:Gas Chromatography-Mass Spectrometry; D006801:Humans; D007700:Kinetics; D011863:Radioimmunoassay; D014268:Trifluoperazine / Q000097:blood
D014150:Antipsychotic Agents; D014268:Trifluoperazine